8-K: OraSure Q3 Revenue Drops 32% Amid Public Health Funding Uncertainty

OraSure Technologies reports a significant 32% decline in Q3 2025 total net revenues to $27.1 million, attributing the drop to public health program funding uncertainty and customer diversification efforts.

Summary

• Total net revenues for Q3 2025 decreased 32% to $27.1 million from $39.9 million in Q3 2024.
• Core revenues, excluding COVID-19, Molecular Services, and Risk Assessment Testing, were $27.0 million, a 25% decrease year-over-year.
• Diagnostics revenues declined 34% to $14.5 million, primarily due to lower revenue from HIV tests.
• Sample Management Solutions revenues decreased 20% to $10.3 million, attributed to a large customer in the consumer genomics segment.
• GAAP operating loss widened to $16.1 million in Q3 2025, compared to an operating loss of $6.0 million in Q3 2024.
• Net loss for Q3 2025 was $13.7 million, compared to $4.5 million in Q3 2024, resulting in a diluted GAAP EPS of $(0.19).
• Cash and cash equivalents stood at $216 million as of September 30, 2025.
• The company deployed $5 million during Q3 to repurchase approximately 1.5 million shares of common stock.
• OraSure signed a definitive agreement to acquire BioMedomics, adding the SickleSCAN rapid test for sickle cell disease to its diagnostic portfolio.
• The company extended its relationship with the Together Take Me Home program for HIV self-tests and was selected by the ENDO1000 project for sample collection devices.
• Q4 2025 total revenue guidance is projected to be between $25 million and $28 million, with less than $100 thousand from COVID-19 testing.

Sentiment

Score: 3

Explanation: While Q3 2025 financial results show significant declines in revenue and widening losses, the company maintains a strong cash position, is executing on strategic acquisitions (BioMedomics), extending key partnerships, and has a pipeline of new products expected to launch in 2026. Management expresses confidence in a return to growth next year, but the current quarter's performance is poor.

Positives

• Non-GAAP gross margin improved to 44.2% in Q3 2025 from 43.3% in Q3 2024.
• Maintained a strong balance sheet with $216 million in cash and no debt as of September 30, 2025, providing financial flexibility.
• Repurchased approximately 1.5 million shares of common stock for $5 million during Q3 2025.
• Acquired BioMedomics, expanding the diagnostic portfolio with SickleSCAN for sickle cell disease, which can leverage existing international sales channels.
• Extended partnership with the U.S. federal government-funded Together Take Me Home program, making HIV self-tests available to at-risk populations.
• Selected by the U.K.-wide ENDO1000 project to provide devices for collection and stabilization of various samples for endometriosis research.
• Anticipated new product launches in 2026, including the Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and Colli-Pee urine self-collection for sexually transmitted infections.
• Appointed Steven K. Boyd to the Board of Directors as part of ongoing refreshment efforts, bringing valuable shareholder perspective and public markets experience.

Negatives

• Total net revenues decreased 32% to $27.1 million in Q3 2025 from $39.9 million in Q3 2024.
• Core revenues decreased 25% year-over-year to $27.0 million.
• Diagnostics revenues decreased 34% to $14.5 million, primarily due to lower HIV test revenue.
• Sample Management Solutions revenues decreased 20% to $10.3 million, attributed to a large customer in the consumer genomics segment.
• GAAP operating loss significantly widened to $16.1 million in Q3 2025 from $6.0 million in Q3 2024.
• Non-GAAP operating loss widened to $12.7 million in Q3 2025 from $2.7 million in Q3 2024.
• Net loss increased to $13.7 million in Q3 2025 from $4.5 million in Q3 2024.
• Diluted GAAP EPS worsened to $(0.19) in Q3 2025 from $(0.06) in Q3 2024.
• Cash and cash equivalents decreased from $267.8 million at December 31, 2024, to $216.5 million at September 30, 2025.
• Operating activities used $40.0 million cash for the nine months ended September 30, 2025, a significant reversal from $27.3 million provided in the same period of 2024.
• Customers continue to experience elevated levels of uncertainty related to funding for public health programs and research.

Risks

• Ability to satisfy customer demand.
• Ability to reduce spending rate, capitalize on manufacturing efficiencies, and drive profitable growth.
• Impact of significant customer concentration in the genomics business.
• Failure of distributors or other customers to meet purchase forecasts, historic purchase levels, or minimum purchase requirements for products.
• Ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications.
• Ability to comply with applicable regulatory requirements and effectively resolve warning letters, audit observations, and other findings from regulators.
• Changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for critical activities.
• Impact of replacing distributors and inventory levels at distributors and other customers.
• Ability to achieve financial and strategic objectives and increase revenues, including expanding international sales and reducing costs.
• Impact of competitors, competing products, and technology changes.
• Reduction or deferral of public funding available to customers.
• Competition from new or better technology or lower cost products.
• Ability to develop, commercialize, and market new products.
• Market acceptance of products and services, including changes in testing guidelines, algorithms, or other recommendations by health agencies.
• Ability to fund research and development and other products and operations.
• Ability to obtain and maintain new or existing product distribution channels.
• Reliance on sole supply sources for critical products and components.
• Impact of contracting with the U.S. government.
• Impact of negative economic conditions, including interest rates, inflationary pressures, capital market disruptions, and economic slowdowns or recessions.
• Ability to achieve and maintain sustained profitability and increase gross margins.
• Ability to utilize net operating loss carry forwards or other deferred tax assets.
• Uncertainty relating to patent protection and potential patent infringement claims, and the costs of litigation.
• Adverse movements in foreign currency exchange rates.
• Loss or impairment of sources of capital.
• Ability to attract and retain qualified personnel.
• Exposure to product liability and other types of litigation.
• Changes in international, federal, or state laws and regulations.
• Cybersecurity incidents and other disruptions involving computer systems or those of third-party IT service providers, suppliers, and customers.
• The impact of terrorist attacks, civil unrest, hostilities, and war.

Future Outlook

OraSure Technologies anticipates a return to growth in 2026, driven by ongoing customer diversification efforts and the planned launches of new products, including the Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae, and the Colli-Pee urine self-collection device for sexually transmitted infections. For Q4 2025, the company provides total revenue guidance of $25 million to $28 million, with minimal contribution from COVID-19 testing (less than $100 thousand), and expects non-GAAP gross margin to be in the low 40% range. The company also aims for a path to 50% adjusted gross margin as sales volumes increase.

Management Comments

• "In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions." Carrie Eglinton Manner, President and CEO.
• "OTI’s focus on decentralizing diagnostics and connecting people to care that is more accessible, convenient, private, and personalized is well-aligned with important long-term trends in the healthcare industry. We believe that this strategy and our capabilities position us for sustainable, long-term growth." Carrie Eglinton Manner, President and CEO.
• "Additionally, our strong balance sheet provides us with flexibility to navigate the current short-term turbulence while we advance our innovation roadmap and prepare for important new products that are expected to launch next year, including our Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae and our Colli-Pee urine self-collection for sexually transmitted infections." Carrie Eglinton Manner, President and CEO.

Industry Context

OraSure Technologies' Q3 2025 performance reflects broader industry challenges, particularly the impact of elevated uncertainty in public health program funding and research, which affects customer purchasing. However, the company's strategic focus on decentralizing diagnostics and enhancing accessibility aligns with significant long-term trends in the healthcare industry towards more convenient and personalized care. The acquisition of BioMedomics and its SickleSCAN product positions OraSure to expand its global health footprint, leveraging existing international channels. Participation in initiatives like the ENDO1000 project also highlights the growing demand for advanced sample collection solutions in specialized research and diagnostics.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Experienced negative impact from significant revenue decline, widening losses, and worsening EPS. Potential positive from share repurchase and future growth prospects tied to new product launches and strategic acquisitions.
• Employees: The company's 'Org right-sizing' and 'reduced headcount' initiatives, mentioned as part of its transformation strategy, indicate past or ongoing impact on the workforce.
• Customers: Facing uncertainty related to funding for public health programs and research, which could affect demand. However, new product launches and extended partnerships aim to improve and diversify customer offerings.
• Creditors: The company's strong cash position ($216 million) and absence of debt mitigate immediate concerns despite operating losses.

Next Steps

• Launch of Sherlock over-the-counter molecular self-test for Chlamydia and Gonorrhoeae (expected next year).
• Launch of Colli-Pee urine self-collection for sexually transmitted infections (expected next year).
• Complete clinical study for Colli-Pee for multiple STIs and submit to FDA late 2025 / early 2026.
• Complete clinical study for Sherlock CT/NG initial assay and submit to FDA late 2025 / early 2026.
• Undergo regulatory review for HEMAcollect Dot initial application, with future launch via distribution agreement.
• Continue efforts to diversify customer base and reduce product costs.
• Advance innovation roadmap and prepare for new product launches.
• Achieve anticipated benefits from the BioMedomics transaction.
• Monitor Q4 2025 total revenues (guided $25 million to $28 million) and non-GAAP gross margin (guided low 40% range).

Key Dates

Recommendation

While the Q3 2025 financial results are significantly negative with substantial revenue declines and widening losses, the company maintains a strong balance sheet with $216 million in cash and no debt. Management has outlined a clear strategy for returning to growth in 2026 through customer diversification, strategic acquisitions like BioMedomics, and a pipeline of promising new products (Sherlock, Colli-Pee) expected to launch next year. The current quarter reflects short-term turbulence, particularly from public health funding uncertainty, but the long-term strategic alignment with decentralized diagnostics and innovation roadmap suggests potential for recovery. Investors should hold to monitor the execution of the growth strategy and the performance of new product launches.

Keywords

OraSure Technologies, OSUR, financial results, Q3 2025, diagnostics, sample management, HIV tests, consumer genomics, BioMedomics, SickleSCAN, public health funding, molecular diagnostics, Chlamydia, Gonorrhoeae, Colli-Pee, endometriosis, corporate governance, share repurchase, revenue decline, operating loss